Meeting
2020 Genitourinary Cancers Symposium
Analysis of the prognostic significance of circulating tumor DNA (ctDNA) in metastatic castrate-resistant prostate cancer (mCRPC).
Authors
Justin Shaya
University of California San Diego Moores Cancer Center, San Diego, CA
Justin Shaya , James Michael Randall , Frederick E. Millard , Razelle Kurzrock , J Kellogg Parsons , Pablo Tamayo , Rana R. McKay
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr 110)
Abstract #
110
Poster Bd #
E12
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Association of a prostate cancer gastrointestinal transcriptional phenotype as found in clinical mCRPC samples with response to AR-targeted therapy.
First Author: Aishwarya Subramanian
Poster
2023 ASCO Genitourinary Cancers Symposium
Alliance A031902 (CASPAR): A randomized phase (ph) 3 trial of enzalutamide with rucaparib/placebo in first-line metastatic castration-resistant prostate cancer (mCRPC).
First Author: Arpit Rao
Poster
2022 ASCO Genitourinary Cancers Symposium
Liquid biopsy AR/enhancer alteration detection before AR-targeted therapy and correlation with survival in metastatic castrate-resistant prostate cancer patients.
First Author: Alexander Shiang
Poster
2020 Genitourinary Cancers Symposium
Treatment response comparisons between ATM and BRCA2 germline carriers for mCRPC.
First Author: Alexandra Sokolova